Will UK's IP Commercialization Model Go Trans-Atlantic Soon?
This article was originally published in Scrip
Executive Summary
IP commercialization may be all the rage for company creation in the UK, but it remains comparatively unknown in the US. The CEOs of two Boston-based groups using that business approach – Allied Minds PLC and PureTech Health PLC – spoke to Scrip's sister publication Start-Up about their firms' strategies for creating and developing life science businesses using the model.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.